VitD3 Supplementation in Patients With Multiple Myeloma
NCT05846880
Age 18 +
Sex Both
Phase Early Phase 1
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key details about the study:
- The treatment involves a combination of multiple drugs that work together to target the cancer cells more effectively.
- This study is unique because it looks at how these drugs can be used in different combinations to find the most effective treatment plan for patients.
- Patients will receive the treatment in a controlled environment, allowing researchers to closely monitor their progress and any side effects.
- The study aims to determine the best dosage and timing for administering the drugs to maximize their effectiveness.
- Researchers will also evaluate how well the treatment works over time, looking at factors like the reduction of cancer cells and overall patient health.
- Participants will be closely followed for several months to gather data on the treatment's impact.
Third Opinion AI Generated Synopsis
Trial Summary
The goal of this clinical trial is to evaluate post-transplant immune reconstitution and lymphocyte recovery as well as the 3-year progression-free survival of patients with multiple myeloma in two treatment arms. One arm will receive Maintenance Vitamin D and the other arm will receive no maintenance Vitamin D prior to ASCT. Post ASCT arm 1 will have lenalidomide and maintenance VitD, and arm 2 will receive lenalidomide and no maintenance VitD. This clinical trial will also evaluate the overall response rate and survival for both treatment arms.
The goal of this clinical trial is to evaluate post-transplant immune reconstitution and lymphocyte recovery as well as the 3-year progression-free survival of patients with multiple myeloma in two treatment arms. One arm will receive Maintenance Vitamin D and the other arm will receive no maintenance Vitamin D prior to ASCT. Post ASCT arm 1 will have lenalidomide and maintenance VitD, and arm 2 will receive lenalidomide and no maintenance VitD. This clinical trial will also evaluate the overall response rate and survival for both treatment arms.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
